Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1B/II Study of Pevonedistat + Cytarabine + Idarubicin in Newly Diagnosed High Risk AML
NCT03330821Phase 2Active, not recruiting
- Sponsor
- University of Southern California
- Start
- Apr 2018
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pevonedistat in acute myeloid leukemia (AML), sponsored by University of Southern California. Started Apr 2018; status: active, not recruiting.
02
Drugs
pevonedistat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03330821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03330821.